Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 2007-2010, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bizzaro, N.
Right arrow Articles by Finco, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bizzaro, N.
Right arrow Articles by Finco, B.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 1999;45:2007-2010.)
© 1999 American Association for Clinical Chemistry, Inc.

Technical Briefs

False-Positive Reactions for IgA Anti-Phospholipid and Anti-ß2-Glycoprotein I Antibodies in Patients with IgA Monoclonal Gammopathy

Nicola Bizzaroa, Paola Pasini and Bruno Finco

a author for correspondence: fax 00-39-0421-227571, e-mail nbizzaro@dacos.it

We report here that measurements of IgA anti-cardiolipin (aCL) and anti-ß2-glycoprotein I (ß2GPI) antibodies are unreliable in patients with IgA monoclonal gammopathies (MGs). MGs are characterized by monoclonal immunoglobulins produced by a proliferating B-lymphocyte clone. Monoclonal gammopathy of undetermined significance (MGUS) is the most common type of MG (1); the monoclonal component (MC) is IgA in 15–25% of MGs (2).

aCL antibodies, originally described in patients with systemic lupus erythematosus (3), have been detected in patients with other autoimmune diseases (4)(5) and in the antiphospholipid syndrome (6)(7) as well as in nonrheumatologic disorders (8) and in healthy individuals (9)(10)(11). In patients with connective tissue diseases and antiphospholipid syndrome, aCL antibodies are most frequently IgG, followed by IgM. Kalunian et al. (12), however, reported a high incidence of IgA, rather than IgG-aCL antibodies associated with thrombosis and fetal loss, and other reports have suggested that IgA-aCL antibodies may have a clinical meaning even in the absence of IgG- or IgM-aCL (13)(14)(15)(16)(17)(18)(19)(20)(21). Their prevalence in healthy subjects seems negligible; in a series of 389 healthy pregnant women, Lynch et al. (22) found only one positive case (0.3%). Therefore, to properly assess the risk of thrombosis, thrombocytopenia, and recurrent abortions in systemic lupus erythematosus patients, the determination of IgA-aCL antibodies has been recommended (18)(21). Very recently, the same recommendation was also made for anti-ß2GPI antibody determination because anti-ß2GPI restricted to the IgA isotype can be found in the sera of systemic lupus erythematosus patients with thrombosis (23).

IgG- or . . . [Full Text of this Article]


Footnotes


References




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Pathol.Home page
A. McLean-Tooke, C. Stroud, A. Sampson, and G. Spickett
Falsely normal C4 in a case of acquired C1 esterase inhibitor deficiency
J. Clin. Pathol., May 1, 2007; 60(5): 565 - 566.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.